GET THE APP

Compensatory angiogenesis and tumor refractoriness
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Compensatory angiogenesis and tumor refractoriness


9th Indo Global Summit on Cancer Therapy

November 02-04, 2015 Hyderabad, India

Rajesh N Gacche

Swami Ramanand Teerth Marathwada University, India

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Since the establishment of tumor angiogenesis as a therapeutic target, an excitement in developing the anti-angiogenic agents was resulted in tailoring a humanized monoclonal antibody (Bevacizumab) against vascular endothelial growth factor (VEGF): A key factor in recruiting angiogenesis. The past three decades├ó┬?┬? research in the area of angiogenesis also invented a series of novel and effective anti-angiogenic agents targeting the VEGF signaling axis. Despite the demonstrable clinical benefits of anti-angiogenic therapy, the preclinical and clinical data of the current therapeutic settings clearly indicate the transient efficacy, restoration of tumor progression and aggressive recurrence of tumor invasion after the withdrawal of anti-angiogenic therapy. Therefore, the impact of this therapeutic regime on improving overall survival of patients has been disappointing in clinic. The recent advances in pathophysiology of tumor angiogenesis and related molecular and cellular under-pinning attributed the conspiracy of compensatory angiogenic pathways in conferring evasive and intrinsic tumor resistance to anti-angiogenic agents. The understandings of how these pathways functionally cross-talk for sustaining tumor angiogenesis during VEGF blockade is essential and perhaps may act as a basic prerequisite for designing novel therapeutic strategies to combat the growing arrogance of tumors toward anti-angiogenic agents. An elaborative discourse on major compensatory angiogenic pathways operating at cellular and molecular levels and their attributes with resistance to anti-angiogenic agents along with strategic opinions on future setting in targeting tumor angiogenesis will be discussed.

Biography :

Rajesh N Gacche has completed M. Sc. SET, CSIR NET-JRF, B.G.L., LLB., PhD. At present, he is working as a Professor in Tumor Biology Laboratory, School of Life Sciences, S. R. T. M. University, Nanded (Maharashtra).

Email: rngacche@rediffmail.com

Google Scholar citation report
Citations: 3644

Cancer Science & Therapy received 3644 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward